EGFR and breast cancer: In summary, the results indicate that a decrease in hydrogen peroxide by CAT-SKL treatment in combination with an EGFR inhibitor holds promise of a novel, therapeutic modality to treat TNBC, a breast cancer subtype with the worst prognosis and high need for treatment options.